	US 12,253,520 B2
	Compositions and methods for assaying platelet reactivity and treatment selection
David Schneider, Burlington, VT (US)
Assigned to University of Vermont and State Agricultural College
Filed by University of Vermont and State Agricultural College, Burlington, VT (US)
Filed on Jul. 17, 2023, as Appl. No. 18/353,683.
Application 16/668,397 is a division of application No. 14/403,337, granted, now 10,502,737, issued on Dec. 10, 2019, previously published as PCT/US2013/042540, filed on May 23, 2013.
Application 18/353,683 is a continuation of application No. 16/668,397, filed on Oct. 30, 2019, granted, now 11,747,335.
Claims priority of provisional application 61/651,779, filed on May 25, 2012.
Prior Publication US 2023/0358744 A1, Nov. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/53 (2006.01); A61K 31/4365 (2006.01); A61K 31/443 (2006.01); A61K 31/519 (2006.01); G01N 33/569 (2006.01); G01N 33/68 (2006.01); G01N 33/86 (2006.01)

CPC G01N 33/56966 (2013.01) [A61K 31/4365 (2013.01); A61K 31/443 (2013.01); A61K 31/519 (2013.01); G01N 33/6854 (2013.01); G01N 33/86 (2013.01); G01N 2333/70535 (2013.01); G01N 2800/222 (2013.01); G01N 2800/226 (2013.01); G01N 2800/52 (2013.01)]

19 Claims

1. A method of treating a selected subject with an anti-thrombotic therapy, the method comprising:

administering an anti-thrombotic agent to the selected subject, wherein the subject is selected by detecting a level of copies of FcγRIIa per platelet from the subject and comparing the level of copies of FcγRIIa per platelet from the subject against a level of copies of FcγRIIa per platelet from a healthy individual, wherein a level increased by at least about 1.5 fold of FcγRIIa per platelet identifies the subject as at risk of thrombosis and in need of anti-thrombotic therapy, wherein the anti-thrombotic agent comprises aspirin.